Ryan Din, MD
Allergy & Immunology · Boston, MANPI 1679139133
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,405 of the $6,459 with a category attached, or 68.2%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.4%. 2025 is the largest year on record at $3,416, 3.4 times the $1,000 reported in 2022.
Across 149 payments — averaging $43.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AbbVie$1K
- Regeneron$1K
- AstraZeneca$636
- Regeneron Healthcare Solutions, Inc.$477
- Galderma Laboratories, L.p.$328
- plus $2K from 20 others
What the payments were for
- Grants$1,80028%
- Travel & lodging$631%
- Food & beverage$4,40568%
- Education$1913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $1,189 |
| AbbVie | 21 | $1,068 |
| Regeneron | 1 | $1,000 |
| AstraZeneca | 18 | $636 |
| Regeneron Healthcare Solutions, Inc. | 23 | $477 |
| Galderma Laboratories, L.p. | 10 | $328 |
| Pfizer | 6 | $192 |
| Incyte Corporation | 4 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $185 |
| Biocryst US Sales Co., LLC | 6 | $174 |
| Grifols USA, LLC | 2 | $127 |
| CSL Behring | 5 | $125 |
| GSK | 6 | $122 |
| Novartis | 4 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $93 |
| Organon | 5 | $92 |
| GC Biopharma USA, Inc. | 3 | $84 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $54 |
| Amgen | 2 | $41 |
| Ferring Pharmaceuticals Inc. | 1 | $38 |
| Genentech USA, Inc. | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $30 |
| Optinose US, Inc. | 1 | $28 |
| Pharming Healthcare, Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,459 in reported general payments places this provider in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $42,227 |
| Spiriva RespimatTiotropium Bromide | 19 | $14,858 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $562 |
| Montelukast Sodium | 16 | $250 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Boston
- Wanda PhipatanakulBoston$679K
- Kathleen BuchheitBoston$224K
- Aleena BanerjiBoston$133K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Matthew GiannettiBoston$55K
- Aidan LongBoston$43K
- Wayne MarascoBoston$40K
- Michael PistinerBoston$36K
- Jocelyn FarmerBoston$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.